“Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response”
– NR4A1 和 NR4A2 的药理学靶向激活胶质母细胞瘤治疗反应 –
基本信息
- 批准号:10744524
- 负责人:
- 金额:$ 50.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-19 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:Adoptive TransferAdultAutomobile DrivingBioinformaticsBiological AssayBiologyCancer ModelCarcinomaCell LineCell ProliferationCell physiologyCellsCessation of lifeClinical TrialsDataDrug KineticsExhibitsFutureGene ExpressionGenesGeneticGlioblastomaGoalsHumanIL8 geneImmuneImmune EvasionImmune checkpoint inhibitorImmune responseImmunooncologyImmunosuppressionImmunotherapyIndolesInfiltrationInvadedLeadLigandsMacrophageMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of brainMeasuresMediatingMesenchymalMesenchymal Cell NeoplasmModelingMolecularMusMyeloid CellsMyeloid-derived suppressor cellsNR4A1 geneNR4A2 geneNuclear Orphan ReceptorOrphan Nuclear Receptor GeneOutcomePatientsPharmaceutical ChemistryPharmaceutical PreparationsPhenotypePre-Clinical ModelPreclinical TestingProductionProliferatingPropertyRadiation therapyReceptor InhibitionRegulationRegulatory T-LymphocyteResistanceRoleSeriesSignal TransductionT cell differentiationT-LymphocyteTWIST1 geneTestingTherapeuticToxic effectTumorigenicityantagonistanti-cancerbioinformatics toolcandidate identificationcheckpoint therapychemoradiationconventional therapycytokinecytotoxicityexhaustexhaustionimprovedin vivoin vivo evaluationknock-downloss of functionmigrationmultidisciplinaryneoplastic cellneuro-oncologynovelnovel strategiesnovel therapeuticspharmacologicpre-clinicalprogrammed cell death ligand 1programsradiation resistancereceptorreceptor expressionresponseself-renewalsingle-cell RNA sequencingstandard of carestem cell self renewalstemnesstemozolomidetherapy resistanttreatment responsetumortumor growthtumor microenvironmenttumor-immune system interactions
项目摘要
Resistance to standard of care (SOC) temozolomide (TMZ) and radiation treatment (XRT) limits survival of the
most common adult brain cancer, glioblastoma (GBM), to 12-18 months. Despite promising results in other
cancers, robust immunosuppression in GBM has also limited the responses to immune checkpoint inhibitors
(ICIs). Reciprocal interactions in the GBM tumor microenvironment (TME) between mesenchymal changes and
immunosuppression enhance resistance to chemoradiation and immunotherapy, respectively. Therefore, a
compelling therapeutic strategy for GBM is to concurrently reprogram the mesenchymal and immune
suppressive TMEs and potentiate ICI and SOC therapy. The NR4A1 and NR4A2 orphan nuclear receptors are
compelling targets to achieve this goal. We synthesized a series of novel bis-indole–derived ligands (CDIMs)
with potent dual antagonism of NR4A1 and NR4A2 and negligible in vivo toxicity, of which six demonstrated nM
range KDs for both receptors. Genetic based NR4A 1 and 2 loss of function strongly activates anti-cancer
immune responses by reversing T-cell exhaustion which underlies poor ICI responses in GBM. In addition,
NR4A1/2 promote EMT in other cancers which contributes to chemoradiation resistance. Finally, high levels of
NR4A1/2 expression in GBM are strongly associated with decreased patient survival after conventional
treatments. Therefore, we propose to test the hypothesis that CDIM inhibition of NR4A1/2 reprograms the
GBM TME and potentiates ICI and TMZ/XRT responses. Further NR4A1/2 upregulates PD-L1 and TWISt1,
key regulators of GBM immune suppression and mesenchymal phenotypes, respectively. Preliminary studies
demonstrated that CDIMs inhibit PD-L1 and TWIST1 expression, reverse immune suppressive myeloid and T
cell phenotypes and prolong survival of experimental GBMs. We will test our hypothesis by i) identifying lead
dual NR4A1/2 CDIM compounds based on inhibition of malignant and mesenchymal GBM cell properties
(proliferation, self-renewal, invasion) and reversal of dysfunctional T cell phenotypes in vivo (Aim 1), ii)
establishing the functional impact of NR4A1/2 CDIMs to reprogram the immune suppressive and mesenchymal
TME (Aim 2) and iii) quantifying the effects of NR4A1/2 CDIMs to potentiate ICI and SOC responses in mouse
GBM syngeneic models and define the role of PD-L1 and TWIST1 in their mechanisms of action (Aim 3).
Quantification of potency, pharmacokinetics and preclinical anti-tumor activity alone and in combination with to
standard of care TMZ-XRT and ICIs is expected to identify candidate CDIMs for consideration in future clinical
trials. Through application of powerful bioinformatic tools that model the cancer TME through integration of
scRNAseq, cyTOF and IMC data, these studies are expected to shed new light on novel mechanisms by which
mesenchymal and immune suppressive TMEs interact to coordinately drive treatment resistance in GBM through
NR4A1/2. To achieve our goals, we assembled a unique multidisciplinary team with expertise in medicinal
chemistry, neuro-oncology, GBM biology and preclinical modeling, and immuno-oncology.
对标准护理 (SOC) 替莫唑胺 (TMZ) 和放射治疗 (XRT) 的抵抗限制了患者的生存
最常见的成人脑癌是胶质母细胞瘤 (GBM),发病年龄为 12-18 个月。尽管在其他方面取得了可喜的成果
癌症,GBM 中强大的免疫抑制也限制了对免疫检查点抑制剂的反应
(ICIs)。 GBM肿瘤微环境(TME)中间充质变化和
免疫抑制分别增强对放化疗和免疫治疗的抵抗力。因此,一个
GBM 引人注目的治疗策略是同时重新编程间充质和免疫细胞
抑制 TME 并增强 ICI 和 SOC 治疗。 NR4A1 和 NR4A2 孤儿核受体是
实现这一目标的紧迫目标。我们合成了一系列新型双吲哚衍生配体(CDIM)
具有 NR4A1 和 NR4A2 的强效双重拮抗作用,体内毒性可忽略不计,其中 6 种表现出 nM
两种受体的 KD 范围。基于基因的 NR4A 1 和 2 功能丧失可强烈激活抗癌作用
通过逆转 T 细胞耗竭来调节免疫反应,而 T 细胞耗竭是 GBM 中 ICI 反应不佳的基础。此外,
NR4A1/2 促进其他癌症的 EMT,从而导致放化疗耐药。最后,高水平
GBM 中的 NR4A1/2 表达与常规治疗后患者生存率下降密切相关
治疗。因此,我们建议检验以下假设:CDIM 抑制 NR4A1/2 会重新编程
GBM TME 并增强 ICI 和 TMZ/XRT 反应。 NR4A1/2 进一步上调 PD-L1 和 TWISt1,
分别是 GBM 免疫抑制和间充质表型的关键调节因子。初步研究
证明 CDIM 抑制 PD-L1 和 TWIST1 表达,逆转免疫抑制性骨髓和 T
细胞表型并延长实验性 GBM 的存活时间。我们将通过 i) 识别铅来检验我们的假设
基于抑制恶性和间充质 GBM 细胞特性的双重 NR4A1/2 CDIM 化合物
(增殖、自我更新、入侵)和体内功能失调的 T 细胞表型的逆转(目标 1),ii)
确定 NR4A1/2 CDIM 对免疫抑制和间充质细胞重编程的功能影响
TME(目标 2)和 iii)量化 NR4A1/2 CDIM 对增强小鼠 ICI 和 SOC 反应的影响
GBM 同系模型并定义 PD-L1 和 TWIST1 在其作用机制中的作用(目标 3)。
单独和联合使用的效力、药代动力学和临床前抗肿瘤活性的量化
护理标准 TMZ-XRT 和 ICI 预计将确定候选 CDIM,供未来临床考虑
试验。通过应用强大的生物信息工具,通过整合以下各项来模拟癌症 TME
scRNAseq、cyTOF 和 IMC 数据,这些研究有望为新机制提供新的线索
间充质和免疫抑制性 TME 相互作用,通过以下方式协调驱动 GBM 的治疗抵抗:
NR4A1/2。为了实现我们的目标,我们组建了一支独特的多学科团队,拥有医学专业知识
化学、神经肿瘤学、GBM 生物学和临床前建模以及免疫肿瘤学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrei M Mikheev其他文献
Andrei M Mikheev的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrei M Mikheev', 18)}}的其他基金
Generation of TWIST1 reporters through characterization of TWIST1 dependent netwo
通过表征 TWIST1 依赖网络生成 TWIST1 报告基因
- 批准号:
8637397 - 财政年份:2013
- 资助金额:
$ 50.34万 - 项目类别:
Generation of TWIST1 reporters through characterization of TWIST1 dependent netwo
通过表征 TWIST1 依赖网络生成 TWIST1 报告基因
- 批准号:
8719192 - 财政年份:2013
- 资助金额:
$ 50.34万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




